CVALF
Price
$1.90
Change
+$0.09 (+4.97%)
Updated
Jul 3 closing price
Capitalization
52.24M
SMMT
Price
$24.55
Change
+$1.93 (+8.53%)
Updated
Jul 3 closing price
Capitalization
18.23B
32 days until earnings call
Interact to see
Advertisement

CVALF vs SMMT

Header iconCVALF vs SMMT Comparison
Open Charts CVALF vs SMMTBanner chart's image
Covalon Technologies
Price$1.90
Change+$0.09 (+4.97%)
Volume$3.1K
Capitalization52.24M
Summit Therapeutics
Price$24.55
Change+$1.93 (+8.53%)
Volume$12.73M
Capitalization18.23B
CVALF vs SMMT Comparison Chart in %
Loading...
CVALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CVALF vs. SMMT commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVALF is a Buy and SMMT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (CVALF: $1.90 vs. SMMT: $24.55)
Brand notoriety: CVALF and SMMT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CVALF: 61% vs. SMMT: 289%
Market capitalization -- CVALF: $52.24M vs. SMMT: $18.23B
CVALF [@Biotechnology] is valued at $52.24M. SMMT’s [@Biotechnology] market capitalization is $18.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CVALF’s FA Score shows that 0 FA rating(s) are green whileSMMT’s FA Score has 1 green FA rating(s).

  • CVALF’s FA Score: 0 green, 5 red.
  • SMMT’s FA Score: 1 green, 4 red.
According to our system of comparison, SMMT is a better buy in the long-term than CVALF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CVALF’s TA Score shows that 3 TA indicator(s) are bullish while SMMT’s TA Score has 4 bullish TA indicator(s).

  • CVALF’s TA Score: 3 bullish, 5 bearish.
  • SMMT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SMMT is a better buy in the short-term than CVALF.

Price Growth

CVALF (@Biotechnology) experienced а +4.97% price change this week, while SMMT (@Biotechnology) price change was +15.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

SMMT is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SMMT($18.2B) has a higher market cap than CVALF($52.2M). SMMT has higher P/E ratio than CVALF: SMMT (26.36) vs CVALF (17.29). SMMT YTD gains are higher at: 37.574 vs. CVALF (-15.179). CVALF has higher annual earnings (EBITDA): 4.73M vs. SMMT (-235.08M). SMMT has more cash in the bank: 361M vs. CVALF (18M). CVALF has less debt than SMMT: CVALF (609K) vs SMMT (6.45M). CVALF has higher revenues than SMMT: CVALF (33.8M) vs SMMT (0).
CVALFSMMTCVALF / SMMT
Capitalization52.2M18.2B0%
EBITDA4.73M-235.08M-2%
Gain YTD-15.17937.574-40%
P/E Ratio17.2926.3666%
Revenue33.8M0-
Total Cash18M361M5%
Total Debt609K6.45M9%
FUNDAMENTALS RATINGS
CVALF vs SMMT: Fundamental Ratings
CVALF
SMMT
OUTLOOK RATING
1..100
3235
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
95
Overvalued
PROFIT vs RISK RATING
1..100
6837
SMR RATING
1..100
5598
PRICE GROWTH RATING
1..100
6036
P/E GROWTH RATING
1..100
939
SEASONALITY SCORE
1..100
5037

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CVALF's Valuation (63) in the null industry is in the same range as SMMT (95) in the Biotechnology industry. This means that CVALF’s stock grew similarly to SMMT’s over the last 12 months.

SMMT's Profit vs Risk Rating (37) in the Biotechnology industry is in the same range as CVALF (68) in the null industry. This means that SMMT’s stock grew similarly to CVALF’s over the last 12 months.

CVALF's SMR Rating (55) in the null industry is somewhat better than the same rating for SMMT (98) in the Biotechnology industry. This means that CVALF’s stock grew somewhat faster than SMMT’s over the last 12 months.

SMMT's Price Growth Rating (36) in the Biotechnology industry is in the same range as CVALF (60) in the null industry. This means that SMMT’s stock grew similarly to CVALF’s over the last 12 months.

SMMT's P/E Growth Rating (9) in the Biotechnology industry is significantly better than the same rating for CVALF (93) in the null industry. This means that SMMT’s stock grew significantly faster than CVALF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CVALFSMMT
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
53%
Bullish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
CVALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BAFE26.650.24
+0.91%
Brown Advisory Flexible Equity ETF
NJAN50.990.29
+0.58%
Innovator Growth-100 Pwr Buff ETF™ Jan
NFJ12.600.03
+0.24%
Virtus Dividend Interest & Premium Strategy Fund
AUMI55.24-0.07
-0.13%
Themes Gold Miners ETF
FNGD6.34-0.32
-4.80%
MicroSectors™ FANG+™ -3X Invrs Lvrgd ETN

CVALF and

Correlation & Price change

A.I.dvisor tells us that CVALF and SMMT have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CVALF and SMMT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVALF
1D Price
Change %
CVALF100%
+4.97%
SMMT - CVALF
27%
Poorly correlated
+8.53%
GNFT - CVALF
25%
Poorly correlated
-0.51%
AKBLF - CVALF
21%
Poorly correlated
N/A
TARA - CVALF
21%
Poorly correlated
+3.96%
MBIO - CVALF
20%
Poorly correlated
N/A
More